Four Life Sciences Companies Expand In Connecticut

Connecticut’s life sciences industry grows as four companies announce expansions, with one choosing Connecticut for U.S. market entry.

Four life sciences companies have expanded or plan to expand their operations in Connecticut, according to AdvanceCT. The companies include MannKind Corporation, Millstone Medical, ReST Therapeutics, and Revalia Bio.

“Connecticut’s life sciences industry has boomed in recent years,” said John Bourdeaux, President and CEO of AdvanceCT. “Companies are drawn to the region due to the abundance of talent along our state’s Innovation Corridor, stretching from Stamford to New Haven to Hartford, plus established life sciences centers in Danbury and Groton. This large concentration of R&D and STEM talent has sustained other notable companies such as Boehringer Ingelheim’s U.S. headquarters, Pfizer’s largest R&D facility in the U.S., and The Jackson Laboratory for Genomic Medicine.”

Connecticut Life Sciences
(Credit: Adobe Stock / ipopba)

Here’s a rundown of the companies and their growth in Connecticut:

In December 2021, MannKind Corporation, one of the largest pharmaceutical firms in Connecticut, designated its Danbury manufacturing and R&D facility as its new corporate headquarters. The company’s former headquarters was in the Los Angeles area.

MannKind CEO Michael Castagna cited planned expansions of the Danbury facility and its “increasing strategic importance” to the company as reasons for the new designation.

In further growth this year, MannKind added more than 50 jobs in Danbury to keep up with demand for its groundbreaking inhaled formulation treatment for pulmonary arterial hypertension. With over 260 workers already located in Danbury, the facility has the potential to strategically expand its workforce as production lines for this therapeutic effort double and additional pipeline efforts progress.

Medical device and pharmaceutical contract manufacturing and laboratory testing company Millstone Medical (formerly MycoScience) recently relocated into a 25,000-square-foot facility in Bloomfield. The new location will allow the company to triple its employee count and increase service capacity by more than 400%. The $10 million investment in the expanded facility, which is expected to be operational in Q2 2024 and includes a cleanroom, will allow Millstone to offer a variety of new services to life sciences companies in Connecticut.

Paris, France-based ReST Therapeutics recently announced its entry into the U.S. market by choosing New Haven as the location for its U.S. headquarters. The developer of breakthrough therapies to treat complex neurological and psychiatric disorders, including Alzheimer’s and PTSD, is currently in the process of raising a $7.5 million post-seed round which it intends to invest in the state, creating 6 new jobs initially.

ReST has also named Yale University Professor and Chief of Psychiatry at Yale-New Haven Hospital Dr. John Krystal to its scientific advisory board, a testament to the institution’s impact on the New Haven region’s life sciences ecosystem.

ConnecticutHanwha Aerospace Picks Connecticut For International Engines HQ

Hanwha Aerospace picked Cheshire, CT for its International Engines Business Headquarters to take advantage of the skilled workforce and close proximity to key customers. Read more…

Revalia Bio is a Yale spinoff that seeks to revolutionize biomedical innovation by reinventing first-in-human clinical trials through the use of organs donated for research. The team is expanding into Elm City Bioscience Center’s 55 Church St tower. As them company raises seed funding, it has committed to investing more than $10 million and creating over 15 jobs in the city.

“Our state’s successes in the life sciences field are thanks in no small part to higher education partners such as Yale University and UConn,” said Tim Miller, Senior Director of Business Development, Life Sciences at AdvanceCT. “Connecticut boasts the 2nd highest academic bioscience R&D expenditures per capita, the 3rd most biological/biomedical advanced degrees per capita, and the 5th most bioscience venture capital investments per capita. The availability of research partnerships, incubator space, funding opportunities, and available, affordable lab space has made Connecticut an increasingly attractive place to do business over historic bioscience centers such as Boston or California.”

Check out all the latest news related to Connecticut economic development, corporate relocation, corporate expansion and site selection.


Please enter your comment!
Please enter your name here